News - Boehringer Ingelheim, AstraZeneca

Filter

Popular Filters

1 to 25 of 480 results

Potential to fast-track drugs in new Cancer Research UK partnership with AstraZeneca and Pfizer

Potential to fast-track drugs in new Cancer Research UK partnership with AstraZeneca and Pfizer

17-04-2014

British charity Cancer Research UK has joined forces with Anglo-Swedish drug major AstraZeneca and US…

AstraZenecaCancerHealthMajorMedicineOncologyPfizerPharmaceuticalPharmacologyResearchUK

Boehringer Ingelheim posts 2013 financials with currency adjusted sales up 1.4%

Boehringer Ingelheim posts 2013 financials with currency adjusted sales up 1.4%

15-04-2014

German family-owned drug major Boehringer Ingelheim today posted financial results for 2013, noting that,…

Boehringer IngelheimFinancialPharmaceutical

NDA filing for empagliflozin and linagliptin combo accepted by FDA

NDA filing for empagliflozin and linagliptin combo accepted by FDA

14-04-2014

The US Food and Drug Administration has accepted the filing of the New Drug Application for the investigational…

Boehringer IngelheimDiabetesEli LillyempagliflozinJardiancelinagliptinNorth AmericaPharmaceuticalRegulationTradjentaUSA

Interview: AstraZeneca’s oncology expert Susan Galbraith on the company’s exciting pipeline

Interview: AstraZeneca’s oncology expert Susan Galbraith on the company’s exciting pipeline

11-04-2014

The full year report from Anglo-Swedish drug major AstraZeneca (LSE: AZN) in February was full of optimism.…

AstraZenecaInterviewsIressaOncologyPharmaceuticalUK

Starpharma expands accord with AstraZeneca

Starpharma expands accord with AstraZeneca

07-04-2014

Australian biotech firm Starpharma has signed a second, expanded agreement with Anglo-Swedish drug major…

AstraZenecaBiotechnologyOncologyResearchStarpharma

US FDA clears Boehringer Ingelheim’s Pradaxa for additional indications

US FDA clears Boehringer Ingelheim’s Pradaxa for additional indications

07-04-2014

The US Food and Drug Administration has approved German family-owned pharma major Boehringer Ingelheim’s…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaRegulationUSA

AstraZeneca and MRC to create new discovery center in Cambridge

AstraZeneca and MRC to create new discovery center in Cambridge

31-03-2014

Anglo-Swedish drug major AstraZeneca and the UK Medical Research Council (MRC) have entered into a collaboration…

AstraZenecaNorthern EuropePharmaceuticalResearchUK

AstraZeneca acquires full control of Japanese subsidiary

AstraZeneca acquires full control of Japanese subsidiary

26-03-2014

Anglo-Swedish drug major AstraZeneca today announced the completion of the purchase of Sumitomo Chemical’s…

Asia-PacificAstraZenecaJapanMergers & AcquisitionsPharmaceutical

AstraZeneca unit debuts new open innovation platform for partnering programs

25-03-2014

Anglo-Swedish drug major AstraZeneca’s IMED Biotech unit has launched a dedicated web site to support…

AstraZenecaBiotechnologyResearch

Japanese approval for Forxiga and Lonsurf

24-03-2014

Anglo-Swedish drug major AstraZeneca says that Japanese Ministry of Health, Labor and Welfare approved…

Asia-PacificAstraZenecaDiabetesForxigaJapanLonsurfOncologyOno PharmaceuticalOtsukaPharmaceuticalRegulationTaiho Pharmaceutical

EMA/CHMP recommends empagliflozin for approval for type 2 diabetes

23-03-2014

German family-owned drug major Boehringer Ingelheim and partner Eli Lilly of the USA have announce a…

Boehringer IngelheimDiabetesEli LillyempagliflozinEuropeJardiancePharmaceuticalRegulation

NICE draft guidance recommends Boehringer Ingelheim’s Giotrif

NICE draft guidance recommends Boehringer Ingelheim’s Giotrif

17-03-2014

UK drugs watchdog the National Institute for Health and care Excellence (NICE) this morning issued new…

Boehringer IngelheimGiotrifNorthern EuropeOncologyPharmaceuticalPricingRegulationUK

AstraZeneca’s diabetes drug Xigduo launched in UK

AstraZeneca’s diabetes drug Xigduo launched in UK

11-03-2014

Anglo-Swedish drug major AstraZeneca’s type 2 diabetes drug Xigduo is now available in the UK.

AstraZenecaDiabetesPharmaceuticalRegulationUKXigduo

AstraZeneca to establish cancer research program with Korea’s HIDI

AstraZeneca to establish cancer research program with Korea’s HIDI

07-03-2014

Anglo-Swedish pharma major AstraZeneca has signed a memorandum of understanding (MoU) with the South…

Asia-PacificAstraZenecaOncologyPharmaceuticalResearch

Boehringer Ingelheim presents new data for HCV/HIV candidate faldaprevir

Boehringer Ingelheim presents new data for HCV/HIV candidate faldaprevir

06-03-2014

German family-owned pharma major Boehringer Ingelheim announced positive results from STARTVerso 4 in…

Anti-viralsBoehringer IngelheimfaldaprevirPharmaceuticalRegulationResearch

FDA issues CRL on empagliflozin, noting manufacturing deficiencies

FDA issues CRL on empagliflozin, noting manufacturing deficiencies

05-03-2014

There was disappointment today for US drug major Eli Lilly and family-owned German pharma firm Boehringer…

Boehringer IngelheimDiabetesEli LillyempagliflozinNorth AmericaPharmaceuticalProductionRegulationUSA

Amarin files suit against AstraZeneca over Epanova

Amarin files suit against AstraZeneca over Epanova

05-03-2014

US biotech firm Amarin revealed in a Stock Exchange Commission submission that it has filed a complaint…

AmarinAstraZenecaBiotechnologyCardio-vascularEpanovaLegalNorth AmericaOmthera PharmaceuticalsPatentsUSAVascepa

New Ph III data show tiotropium Respimat effective across asthma severities

03-03-2014

German family-owned drug major Boehringer Ingelheim has released new data from large scale, Phase III…

Boehringer IngelheimPharmaceuticalResearchRespimatRespiratory and Pulmonarytiotropium

FDA approves Bydureon Pen for type 2 diabetes

FDA approves Bydureon Pen for type 2 diabetes

03-03-2014

Anglo-Swedish drug major AstraZeneca says the US Food and Drug Administration has approved the Bydureon…

AlkermesAmylinAstraZenecaBristol-Myers SquibbBydureonDiabetesPharmaceuticalRegulationUSA

FDA approves Myalept, the first drug to treat a rare metabolic disease

FDA approves Myalept, the first drug to treat a rare metabolic disease

26-02-2014

The US Food and Drug Administration has approved Myalept (metreleptin for injection) as replacement therapy…

AstraZenecaBristol-Myers SquibbmetreleptinMyaleptNorth AmericaPharmaceuticalRare diseasesRegulationUSA

Ardelyx licenses NaP2b to Sanofi in deal worth up to $198 million

Ardelyx licenses NaP2b to Sanofi in deal worth up to $198 million

25-02-2014

US venture-funded biopharmaceutical company Ardelyx has licensed its novel phosphate transport NaP2b…

ArdelyxAstraZenecaLicensingNaP2bNephrology and HepatologyPharmaceuticalSanofitenapanor

Positive CHMP opinion for Teva’s DuoResp Spiromax for asthma and COPD

22-02-2014

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive…

AstraZenecaDuoResp SpiromaxPharmaceuticalRegulationRespiratory and PulmonarySymbicortTeva Pharmaceutical Industries

Vitae Pharma earns $14 million milestone from Boehringer Ingelheim in Alzheimer's collaboration

Vitae Pharma earns $14 million milestone from Boehringer Ingelheim in Alzheimer's collaboration

20-02-2014

US clinical-stage biotech firm Vitae Pharmaceuticals says it has earned a $14 million milestone payment…

BiotechnologyBoehringer IngelheimFinancialNeurologicalResearchVitae Pharmaceuticals

1 to 25 of 480 results

Back to top